147 related articles for article (PubMed ID: 17316316)
1. Opportunities and challenges for the development of pharmacological therapies for obesity treatment.
Cawthorne MA
Obes Rev; 2007 Mar; 8 Suppl 1():131-6. PubMed ID: 17316316
[No Abstract] [Full Text] [Related]
2. Obesity: the fat lady sings?
Cairns E
Drug Discov Today; 2005 Mar; 10(5):305-7. PubMed ID: 15749277
[No Abstract] [Full Text] [Related]
3. Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines.
Correia ML; Haynes WG
Expert Opin Emerg Drugs; 2005 Aug; 10(3):643-60. PubMed ID: 16083333
[TBL] [Abstract][Full Text] [Related]
4. Challenges in the discovery and development of new agents for the treatment of obesity.
Staten MA
Clin Pharmacol Ther; 2007 May; 81(5):753-5. PubMed ID: 17377527
[TBL] [Abstract][Full Text] [Related]
5. The obesity pipeline: current strategies in the development of anti-obesity drugs.
Cooke D; Bloom S
Nat Rev Drug Discov; 2006 Nov; 5(11):919-31. PubMed ID: 17080028
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological treatment of obesity and syndrome X].
Thissen JP
J Pharm Belg; 2001; 56(2):45-50. PubMed ID: 11396351
[No Abstract] [Full Text] [Related]
7. Reefer sanity.
Wadman M
Fortune; 2003 Nov; 148(11):58, 62. PubMed ID: 14666557
[No Abstract] [Full Text] [Related]
8. [Drug therapy of obesity--from bitter experiences to future possibilities].
Rössner S
Lakartidningen; 2000 Apr; 97(14):1726-8. PubMed ID: 10815399
[No Abstract] [Full Text] [Related]
9. The success of bariatric surgery as treatment of type 2 diabetes should be a call to revitalize anti-obesity drug discovery and development.
Opgenorth TJ
Curr Opin Investig Drugs; 2008 Apr; 9(4):355-6. PubMed ID: 18393101
[No Abstract] [Full Text] [Related]
10. Development of novel medications for use in the treatment of obesity in children will be directed by delineating controls of energy homeostasis.
Sherman PM; Zlotkin SH
Arch Pediatr Adolesc Med; 2003 Aug; 157(8):721. PubMed ID: 12912773
[No Abstract] [Full Text] [Related]
11. Obesity pharmacotherapy from a regulatory perspective: overview and key challenges.
Hutchinson NI; Ryder SW
Clin Pharmacol Ther; 2007 May; 81(5):756-60. PubMed ID: 17392723
[TBL] [Abstract][Full Text] [Related]
12. Drug treatment of obesity.
Bray GA
Psychiatr Clin North Am; 2005 Mar; 28(1):193-217, ix-x. PubMed ID: 15733619
[No Abstract] [Full Text] [Related]
13. [Drug treatment of obesity: present and future].
Pereira Cunill JL; Garćia-Luna PP
An Med Interna; 1997 Jun; 14(6):271-4. PubMed ID: 9410096
[No Abstract] [Full Text] [Related]
14. Dietary supplements for weight loss: challenges in evaluation.
Allison DB
Obes Rev; 2005 May; 6(2):89-92. PubMed ID: 15836458
[No Abstract] [Full Text] [Related]
15. [Pharmacological sheet. Orlistat, oral administration (Xenical, Alli). ].
J Pharm Belg; 2009 Jun; (2):67-8. PubMed ID: 19739531
[No Abstract] [Full Text] [Related]
16. The obesity epidemic: pharmacological challenges.
Bloom SR; Kuhajda FP; Laher I; Pi-Sunyer X; Ronnett GV; Tan TM; Weigle DS
Mol Interv; 2008 Apr; 8(2):82-98. PubMed ID: 18403653
[TBL] [Abstract][Full Text] [Related]
17. The pharmaceutical market for obesity therapies.
Wong D; Sullivan K; Heap G
Nat Rev Drug Discov; 2012 Sep; 11(9):669-70. PubMed ID: 22935797
[No Abstract] [Full Text] [Related]
18. A big issue?
Marnell T
Br J Gen Pract; 2006 Jan; 56(522):57. PubMed ID: 16438818
[No Abstract] [Full Text] [Related]
19. [Xenical--a modern perspective drug for the treatment of obesity (review)].
Mkrtumian AM; Biriukova EV
Ter Arkh; 2007; 79(10):35-9. PubMed ID: 18154143
[No Abstract] [Full Text] [Related]
20. The quest for the antifat pill.
Stipp D
Fortune; 2003 Feb; 147(2):66-7. PubMed ID: 12577860
[No Abstract] [Full Text] [Related]
[Next] [New Search]
